title: Profound retinal ischaemia after ranibizumab administration in an eye with ocular ischaemic syndrome.
abstract: OBJECTIVE
  To report the result of ranibizumab administration in an eye with ocular ischaemic syndrome.
  
  
  METHODS
  Fluorescein angiography, ocular pneumoplethysmography and retinal vessel calibre measurement.
  
  
  RESULTS
  An 85-year-old man with ocular ischaemic syndrome demonstrated vision loss, retinal vessel calibre constriction and profound retinal ischaemia after intravitreal ranibizumab.
  
  
  CONCLUSIONS
  We advise against the use of intravitreal vascular endothelial growth factor inhibitors in eyes with ocular ischaemic syndrome.
authors.affiliation: Department of Ophthalmology, Glostrup Hospital, University of Copenhagen, Denmark. peter.k@dadlnet.dk
authors.forename: Peter Kristian
authors.initials: PK
authors.lastname: Kofoed
authors.forename: Inger Christine
authors.initials: IC
authors.lastname: Munch
authors.forename: Michael
authors.initials: M
authors.lastname: Larsen
mesh_terms: D000369:Aged, 80 and over; D000911:Antibodies, Monoclonal / Q000008:administration & dosage* / Q000009:adverse effects*; D061067:Antibodies, Monoclonal, Humanized; D000075202:Contraindications; D005123:Eye / Q000098:blood supply* / Q000000981:diagnostic imaging; D005451:Fluorescein Angiography; D006801:Humans; D056965:Injections, Intraocular; D007511:Ischemia / Q000139:chemically induced* / Q000175:diagnosis / Q000188:drug therapy* / Q000503:physiopathology; D008297:Male; D010991:Plethysmography / Q000379:methods; D011859:Radiography; D000069579:Ranibizumab; D012171:Retinal Vessels / Q000187:drug effects / Q000503:physiopathology; D013577:Syndrome; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors; D014661:Vasoconstriction; D014786:Vision Disorders / Q000209:etiology; D014822:Vitreous Body
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D042461:Vascular Endothelial Growth Factor A; D000069579:Ranibizumab